Troxipide
Based on 1 Customer Validation
Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.62%
- CAS No.: 30751-05-4
- 화학식: C15H22N2O4
- 분자량:294.35
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
All Calcium Channel Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
>100 μM
Compound: Troxipide
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
|
[PMID: 32619887] |
| MGC-803 | IC50 |
>100 μM
Compound: Troxipide
|
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
|
[PMID: 32619887] |
| PC-3 | IC50 |
>100 μM
Compound: Troxipide
|
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
|
[PMID: 32619887] |
| PC-9 | IC50 |
>100 μM
Compound: Troxipide
|
Antiproliferative activity against human PC9 cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
Antiproliferative activity against human PC9 cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
|
[PMID: 32619887] |
Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Normal control group (NCG) and gastric ulcer group (GUG) rat (5% acetic acid 10 mL/kg/day)[1]
-
Dosage:10, 20, 40, 60 mg/kg
-
Administration:Oral; daily; 2 weeks
-
Result:The levels of these cytokines (IL-17, IL-6, TNF-α, IFN-γ and AP-1) were significantly reduced, suggesting that GU was significantly alleviated.
-
Animal Model:NCG and GUG rat[1]
-
Dosage:40 mg/kg for iv
-
Administration:IV
-
Result:Had a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.
Chemical Information
-
CAS No. 30751-05-4
-
Appearance Solid
-
분자량 294.35
-
화학식 C15H22N2O4
-
Color White to off-white
-
SMILES
O=C(NC1CNCCC1)C2=CC(OC)=C(OC)C(OC)=C2
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
용액&용해도
DMSO : 9.09 mg/mL (30.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1 mg/mL (3.40 mM; ultrasonic and warming and heat to 80°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.91 mg/mL (3.09 mM); Clear solution
This protocol yields a clear solution of ≥ 0.91 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.91 mg/mL (3.09 mM); Clear solution
This protocol yields a clear solution of ≥ 0.91 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (274 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hongbin Guo, et al. Metabolites profiling and pharmacokinetics of troxipide and its pharmacodynamics in rats with gastric ulcer. Sci Rep. 2020 Aug 12;10(1):13619. [Content Brief]
[2]. K Kusugami, et al. Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants. Dig Liver Dis. 2000 May;32(4):305-11. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.3973 mL | 16.9866 mL | 33.9732 mL | 84.9329 mL |
| DMSO | 5 mM | 0.6795 mL | 3.3973 mL | 6.7946 mL | 16.9866 mL |
| 10 mM | 0.3397 mL | 1.6987 mL | 3.3973 mL | 8.4933 mL | |
| 15 mM | 0.2265 mL | 1.1324 mL | 2.2649 mL | 5.6622 mL | |
| 20 mM | 0.1699 mL | 0.8493 mL | 1.6987 mL | 4.2466 mL | |
| 25 mM | 0.1359 mL | 0.6795 mL | 1.3589 mL | 3.3973 mL | |
| 30 mM | 0.1132 mL | 0.5662 mL | 1.1324 mL | 2.8311 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Troxipide Related Classifications
HY-B0758 Related Classifications
Powered by Bioz